| Literature DB >> 31665444 |
Yu Abe1, Hideyoshi Noji2, Tomisato Miura3, Misaki Sugai1, Yumiko Kurosu4, Risa Ujiie4, Naohiro Tsuyama1, Aki Yanagi1, Yukari Yanai1, Takashi Ohba5, Tetsuo Ishikawa6, Kenji Kamiya7, Mitsuaki A Yoshida8, Akia Sakai1.
Abstract
In our previous study, we found that chromosomes were damaged by the radiation exposure from a single computed tomography (CT) examination, based on an increased number of dicentric chromosomes (Dics) formed in peripheral blood lymphocytes after a CT examination. We then investigated whether a cumulative increase in the frequency of Dics and chromosome translocations (Trs) formation could be observed during three consecutive CT examinations performed over the course of 3-4 years, using lymphocytes in peripheral bloods of eight patients (five males and three females; age range 27-77 years; mean age, 64 years). The effective radiation dose per CT examination estimated from the computational dosimetry system was 22.0-73.5 mSv, and the average dose per case was 40.5 mSv. The frequency of Dics formation significantly increased after a CT examination and tended to decrease before the next examination. Unlike Dics analysis, we found no significant increase in the frequency of Trs formation before and after the CT examination, and we observed no tendency for the frequency to decrease before the next CT examination. The frequency of Trs formation was higher than that of Dics formation regardless of CT examination. Furthermore, neither analysis of Dics nor Trs showed a cumulative increase in the frequency of formation following three consecutive CT examinations.Entities:
Keywords: chromosome aberration; chromosome translocation; computed tomography; dicentric chromosome; effective radiation dose
Mesh:
Year: 2019 PMID: 31665444 PMCID: PMC7357232 DOI: 10.1093/jrr/rrz068
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.724
Patient characteristics
| Patient | Sex | Age | Disease | Part of body | Period between | Period between | Days from CT | DLP (mGy·cm) | WAZA-ARI (mSv) | Treatment | Smoking | Past CT | Past other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Male | 63 | Lymphoma | Cervix, chest, | 391 | 380 | 8/16/7 | 2679.70/3695.85/3291.20 | 46.30/57.88/57.17 | (+) Chemo | (−) | (+) | Chest, UGI, PET |
| 2 | Female | 67 | Lymphoma | Cervix, chest, | 331 | 350 | 9/19/7 | 1682.30/4354.12/4222.08 | 30.82/75.22/68.25 | (−) | (+) | (+) | Chest, UGI, PET |
| 3 | Male | 64 | Abnormal chest | Cervix, chest, | 364 | 364 | 7/7/7 | 5856.00 | 54.40/69.47/60.16 | (−) | (+) | (+) | Chest, UGI |
| 4 | Male | 51 | Lymphoma | Cervix, chest, | 341 | 352 | 6/9/7 | 3319.80/3046.10/2635.20 | 61.83/50.67/46.72 | (−) | (+) | (+) | Chest, UGI |
| 5 | Male | 73 | Lymphoma | Chest, abdomen, | 490 | 364 | 7/14/14 | 2448.40/1990.50/1704.20 | 46.22/37.25/32.46 | (+) Chemo | (−) | (+) | Chest, UGI, PET |
| 6 | Female | 27 | Lymphoma | Cervix, chest, | 153 | 358 | 6/15/14 | 1248.00/2059.93/1656.50 | 27.06/35.95/32.73 | (+) Chemo | (−) | (+) | Chest, PET |
| 7 | Male | 77 | CML | Chest, abdomen, | 445 | 280 | 11/14/31 | 3368.50/3064.30/2405.70 | 62.61/56.59/46.98 | (+) TKI | (+) | (+) | Chest, UGI |
| 8 | Female | 63 | Lymphoma | Cervix, chest, | 742 | 700 | 14/7/7 | 3265.60/3113.00/2757.60 | 63.54/64.21/56.96 | (+) Chemo, RT | (−) | (+) | Chest, UGI |
aCTDI was defined using 16 cm phantom. All other CTDI were defined using 32 cm phantom.
b Each effective radiation dose of the CT scan was calculated by the computational dosimetry system (WAZA-ARI).
c Chemotherapy or radiotherapy had been performed at least 3 years before this study. Chemo = chemotherapy (mainly rituximab plus CHOP = cyclophosphamide, doxorubicin, vincristine and prednisolone); TKI = tyrosine kinase inhibitor; RT = radiotherapy
d Patients 2, 4 and 7 had stopped smoking 1 year before this study. Patient 3 was still smoking at the beginning of the study.
e All patients underwent CT scanning more than five times during the past 5 years.
f Treatment with tumor resection without additional chemotherapy or radiotherapy.
Results of dicentric chromosome and translocation analyses
| Patient No. | Blood | DLP (mGy·cm) | Effective | Analysis of dicentrics (Dics) | Analysis of translocations (Trs) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell | Dics | Frequency | Increment | Cell | Cell | Trs | Frequency | Increment | ||||
| 1 | 1B | 2679.70 | 46.30 | 2009 | 7 | 0.348 | 0.1 | 5120 | 2021 | 157 | 7.767 | 0.799 |
| 1A | 2008 | 9 | 0.448 | 5175 | 2043 | 175 | 8.566 | |||||
| 2B | 3695.85 | 57.88 | 2005 | 6 | 0.299 | −0.050 | 5112 | 2018 | 122 | 6.045 | 2.382 | |
| 2A | 2010 | 5 | 0.249 | 5110 | 2017 | 170 | 8.427 | |||||
| 3B | 3291.20 | 57.17 | 2009 | 7 | 0.348 | 0.101 | 5149 | 2033 | 166 | 8.166 | 0.188 | |
| 3A | 2003 | 9 | 0.449 | 5124 | 2023 | 169 | 8.354 | |||||
| 2 | 1B | 1682.30 | 30.82 | 2015 | 11 | 0.546 | 0.201 | 5211 | 2030 | 35 | 1.724 | 1.052 |
| 1A | 2007 | 15 | 0.747 | 5179 | 2018 | 56 | 2.776 | |||||
| 2B | 4354.12 | 75.22 | 2012 | 9 | 0.447 | 0.15 | 5139 | 2002 | 39 | 1.948 | 1.504 | |
| 2A | 2009 | 12 | 0.597 | 5131 | 1999 | 69 | 3.452 | |||||
| 3B | 4222.08 | 68.25 | 2008 | 10 | 0.498 | 0.101 | 5132 | 1999 | 62 | 3.101 | −0.199 | |
| 3A | 2005 | 12 | 0.599 | 5130 | 1998 | 58 | 2.902 | |||||
| 3 | 1B | 5856.00 | 54.40 | 2011 | 9 | 0.448 | 0.2 | 5182 | 2046 | 155 | 7.577 | 2.199 |
| 1A | 2005 | 13 | 0.648 | 5234 | 2066 | 202 | 9.776 | |||||
| 2B | 4119.80 | 69.47 | 2006 | 8 | 0.399 | 0.149 | 5215 | 2059 | 198 | 9.617 | −1.174 | |
| 2A | 2008 | 11 | 0.548 | 5130 | 2025 | 171 | 8.443 | |||||
| 3B | 3321.70 | 60.16 | 2007 | 12 | 0.598 | 0.148 | 5105 | 2015 | 169 | 8.385 | 1.8 | |
| 3A | 2012 | 15 | 0.746 | 5521 | 2180 | 222 | 10.185 | |||||
| 4 | 1B | 3319.80 | 61.83 | 2007 | 8 | 0.399 | 0.045 | 5121 | 2022 | 40 | 1.979 | 1.293 |
| 1A | 2025 | 9 | 0.444 | 5264 | 2078 | 68 | 3.272 | |||||
| 2B | 3046.10 | 50.67 | 2003 | 6 | 0.3 | 0.1 | 5272 | 2081 | 59 | 2.835 | 0.435 | |
| 2A | 2001 | 8 | 0.4 | 5654 | 2232 | 73 | 3.27 | |||||
| 3B | 2635.20 | 46.72 | 2000 | 7 | 0.35 | 0.099 | 5407 | 2135 | 61 | 2.858 | 0.207 | |
| 3A | 2006 | 9 | 0.449 | 5289 | 2088 | 64 | 3.065 | |||||
| 5 | 1B | 2448.40 | 46.22 | 2008 | 16 | 0.797 | 0.098 | 5520 | 2179 | 101 | 4.635 | −0.368 |
| 1A | 2012 | 18 | 0.895 | 5402 | 2133 | 91 | 4.267 | |||||
| 2B | 1990.50 | 37.25 | 2005 | 16 | 0.798 | 0.15 | 5204 | 2054 | 99 | 4.819 | 0.656 | |
| 2A | 2004 | 19 | 0.948 | 5228 | 2064 | 113 | 5.475 | |||||
| 3B | 1704.20 | 32.46 | 2002 | 20 | 0.999 | 0.151 | 5141 | 2030 | 84 | 4.139 | −1.375 | |
| 3A | 2000 | 23 | 1.15 | 5132 | 2026 | 56 | 2.764 | |||||
| 6 | 1B | 1248.00 | 27.06 | 2001 | 5 | 0.25 | 0.149 | 5109 | 1990 | 95 | 4.773 | −0.632 |
| 1A | 2005 | 8 | 0.399 | 5145 | 2004 | 83 | 4.141 | |||||
| 2B | 2059.93 | 35.95 | 2003 | 5 | 0.25 | 0.246 | 5273 | 2054 | 95 | 4.625 | 0.938 | |
| 2A | 2015 | 10 | 0.496 | 5168 | 2013 | 112 | 5.563 | |||||
| 3B | 1656.50 | 32.73 | 2002 | 4 | 0.2 | −0.050 | 5210 | 2030 | 48 | 2.365 | 1.178 | |
| 3A | 2001 | 3 | 0.15 | 5216 | 2032 | 72 | 3.543 | |||||
| 7 | 1B | 3368.50 | 62.61 | 2004 | 6 | 0.299 | 0.1 | 5192 | 2050 | 89 | 4.342 | 3.185 |
| 1A | 2003 | 8 | 0.399 | 5115 | 2019 | 152 | 7.527 | |||||
| 2B | 3064.30 | 56.59 | 2000 | 3 | 0.15 | 0.049 | 5205 | 2055 | 165 | 8.03 | 0.361 | |
| 2A | 2006 | 4 | 0.199 | 5162 | 2038 | 171 | 8.391 | |||||
| 3B | 2405.70 | 46.98 | 2004 | 2 | 0.1 | 0.095 | 5397 | 2131 | 173 | 8.119 | −1.037 | |
| 3A | 2048 | 4 | 0.195 | 5222 | 2062 | 146 | 7.082 | |||||
| 8 | 1B | 3265.60 | 63.54 | 2000 | 17 | 0.85 | 0.15 | 5112 | 1991 | 681 | 34.197 | 0.735 |
| 1A | 2000 | 20 | 1 | 5144 | 2004 | 700 | 34.932 | |||||
| 2B | 3113.00 | 64.21 | 2001 | 14 | 0.7 | 0.1 | 5232 | 2038 | 589 | 28.898 | 3.414 | |
| 2A | 2002 | 16 | 0.8 | 5140 | 2002 | 647 | 32.312 | |||||
| 3B | 2757.60 | 56.96 | 2005 | 12 | 0.599 | 0.15 | 5137 | 2001 | 730 | 36.479 | 5.925 | |
| 3A | 2003 | 15 | 0.749 | 5194 | 2023 | 858 | 42.404 | |||||
a Blood sampling either before (B) or after (A) the first (1), second (2) third (3) CT examination.
b CTDI was defined using 16 cm phantom. All other CTDI were defined using 32 cm phantom.
c Estimated effective radiation dose (whole body exposure dose) according to ICRP 103 using WAZA-ARI.
d Frequency in 100 cells.
e Cell counts were converted to the equivalent number of cells as described in the Materials and Methods section.
Fig. 1Frequency of Dics formation and changes in frequency with three consecutive CT examinations. (A) Analysis of Dics formation before and after each of three CT examinations. The light colored bar indicates the frequency before CT and the dark colored bar indicates the frequency after CT. 1st-B, 2nd-B and 3rd-B: before 1st CT, 2nd CT and 3rd CT, respectively. 1st-A, 2nd-A and 3rd-A: after 1st CT, 2nd CT and 3rd CT, respectively. (B) Comparison of the frequency of Dics formation before and after each CT examination. The frequency of Dics formation increased significantly after each CT examination: (a) 1st CT examination, P = 0.0003; (b) 2nd CT examination, P = 0.008; (c) 3rd CT examination, P = 0.007. (C) Comparison of the frequency of Dics formation before the 1st CT and after the 3rd CT. No significant difference was found (P> 0.05).
Fig. 2Frequency of Trs formation and changes in frequency with three consecutive CT examinations. (A) Analysis of Trs formation before and after each of three CT examinations. The light colored bar indicates the frequency of Trs formation before CT and the dark colored bar indicates the frequencies after CT. 1st-B, 2nd-B and 3rd-B: before 1st CT, 2nd CT and 3rd CT, respectively. 1st-A, 2nd-A and 3rd-A: after 1st CT, 2nd CT and 3rd CT, respectively. CE = cell number converted to the equivalent of 100 cells. (B) Comparison of the frequency of Trs formation before and after each CT examination. No significant difference was found in the frequency of Trs formation in each CT examination. (C) Comparison of the frequency of Trs formation before the 1st CT and after the 3rd CT. No significant difference was found (P> 0.05).